MOLN Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 5.29 |
| 52 Week High | CHF 12.70 |
| 52 Week Low | CHF 3.32 |
| Beta | 0.54 |
| 11 Month Change | -18.57% |
| 3 Month Change | -23.63% |
| 1 Year Change | 20.12% |
| 33 Year Change | -54.94% |
| 5 Year Change | n/a |
| Change since IPO | -73.10% |
Recent News & Updates
Shareholder Returns
| MOLN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.3% | 2.5% | 2.2% |
| 1Y | 20.1% | 16.1% | 31.6% |
Return vs Industry: MOLN exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: MOLN underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| MOLN volatility | |
|---|---|
| MOLN Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MOLN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MOLN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 162 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLN fundamental statistics | |
|---|---|
| Market cap | US$199.93m |
| Earnings (TTM) | -US$69.99m |
| Revenue (TTM) | US$6.71m |
29.8x
P/S Ratio-2.9x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLN income statement (TTM) | |
|---|---|
| Revenue | CHF 6.00m |
| Cost of Revenue | CHF 49.97m |
| Gross Profit | -CHF 43.96m |
| Other Expenses | CHF 18.63m |
| Earnings | -CHF 62.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -732.47% |
| Net Profit Margin | -1,042.84% |
| Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison